Previous 10 | Next 10 |
Moleculin Biotech (NASDAQ: MBRX ) announces data from a presentation entitled, "Targeting Cancer Sanctuary Sites: A Novel Approach to the Treatment of Lung Localized Tumors." More news on: Moleculin Biotech, Inc., Healthcare stocks news, Read more ...
HOUSTON , June 25, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced a presentation at the American A...
NEW YORK, June 23, 2020 (GLOBE NEWSWIRE) -- Life Sciences Investor Forum today announced the agenda for its second quarterly event for public and private companies, investors and industry professionals from around the world. This day-long virtual event will showcase live company presentatio...
Moleculin Biotech (NASDAQ: MBRX ) announces that repeat testing of candidate WP122 confirmed its antiviral potential against a surrogate of SARS-CoV-2 called HCoV-229E. More news on: Moleculin Biotech, Inc., Healthcare stocks news, Stocks on the move, Read more ...
HOUSTON , June 16, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates, today announced that a repeat of previous in vitro testing has corroborated the antiviral pote...
IZEA Worldwide (NASDAQ: IZEA ) +79% . More news on: IZEA Worldwide, Inc., Second Sight Medical Products, Inc., Immuron Limited, Stocks on the move, , Read more ...
HOUSTON , June 4, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates, today announced that it has submitted requests to Polish regulatory authorities for approval to...
Moleculin Biotech (NASDAQ: MBRX ) begins patient enrollment in the Emory University Phase 1 clinical trial of WP1066 for the treatment of brain tumors in children. More news on: Moleculin Biotech, Inc., Healthcare stocks news, Read more ...
HOUSTON , June 2, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates, today announced that recruiting has begun and the first patient has been enrolled in the Emory...
HOUSTON , May 27, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that it has received notification...
News, Short Squeeze, Breakout and More Instantly...
Moleculin Biotech Inc. Company Name:
MBRX Stock Symbol:
NASDAQ Market:
Moleculin Biotech Inc. Website:
Moleculin Completes End of Phase 2 Meeting with FDA for Annamycin in AML PR Newswire HOUSTON , July 10, 2024 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfoli...
2024-06-17 10:10:00 ET June 17, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the first of a two-part series looking at developments for the treatment of blood cancers. Today's snapshot focuses in on acute myeloid leukemia (AML) and the compan...
Moleculin Announces Additional Positive Preliminary Interim Data from AML Clinical Trial PR Newswire – 89% of CRc's were subjects with "poor prognosis" cytogenetics and/or mutations – Current median durability of response (mDOR) of CRc's = 6 months and in...